IllnessPituitary tumors, differential diagnosis
Summary
Comprehensive differential diagnostic panel for pituitary tumors comprising 11 or 25 curated genes according to the clinical signs
52,0 kb (Extended panel: incl. additional genes)
- EDTA-anticoagulated blood (3-5 ml)
NGS +
[Sanger]
Gene panel
Selected genes
Name | Exon Length (bp) | OMIM-G | Referenz-Seq. | Heredity |
---|---|---|---|---|
AIP | 993 | NM_003977.4 | AD | |
CDKN1B | 597 | NM_004064.5 | AD, Sus | |
GNAS | 1185 | NM_000516.7; NM_016592.3; NM_080425.3 | AD | |
GPR101 | 1527 | NM_054021.2 | XL | |
MEN1 | 1833 | NM_130799.2 | AD | |
PRKAR1A | 1146 | NM_002734.5 | AD | |
SDHB | 843 | NM_003000.3 | AD | |
SDHC | 510 | NM_003001.5 | AD | |
SDHD | 480 | NM_003002.4 | AD | |
USP48 | 3259 | NM_001032730.3 | AD | |
USP8 | 3357 | NM_005154.5 | AR | |
CDH23 | 10065 | NM_022124.6 | AR | |
CDKN1A | 495 | NM_078467.3 | AD | |
CDKN2B | 417 | NM_004936.4 | AD | |
CDKN2C | 507 | NM_001262.3 | AD | |
DICER1 | 5769 | NM_177438.3 | AD, Sus | |
MAX | 483 | NM_002382.5 | AD | |
MLH1 | 2271 | NM_000249.4 | AD | |
MSH2 | 2805 | NM_000251.3 | AD | |
MSH6 | 4083 | NM_000179.3 | AD | |
PMS2 | 2589 | NM_000535.7 | AD | |
PRKACB | 1423 | NM_001242857.3 | AD | |
RET | 3345 | NM_020975.6 | AD | |
SDHA | 1995 | NM_004168.4 | AR, AD |
Informations about the disease
Pituitary adenomas (PAs) are common lesions in adults, occurring in 15-20% of radiologic findings. On imaging in children, these tumors are rare (0.2%). Although most PAs identified are incidental findings with no need for intervention, some are clinically relevant, because they secrete hormones or cause symptoms by compression or invasion of surrounding tissue. The etiology of PAs is diverse, with no known genetic causes for more than half of the PAs. In certain cases, germline or somatic genetic defects are associated with the development of PAs. Defined as a (distant) metastasis of a PA, pituitary carcinoma (PC) is a rare form of malignant intracranial neoplasm. The incidence of PC is low, with only 0.1-0.2% of PAs developing into PCs; the prognosis remains very poor. The lack of efficacy of current therapies is largely due to the limited understanding of the molecular pathogenesis of PAs and their malignant transformation into PCs. The DNA diagnostic yield is probably comparatively low and currently unknown overall, so that a clinical diagnosis can by no means be ruled out by a negative molecular genetic result.
References: https://www.ncbi.nlm.nih.gov/books/NBK97965/
doi: 10.3390/jcm9010030
- Allelic: ACTH-independent macronodular adrenal hyperplasia (GNAS)
- Allelic: Acrodysostosis 1, with/-out hormone resistance (PRKAR1A)
- Allelic: Adenocarcinoma of lung, somatic (BRAF)
- Allelic: Adrenal adenoma, somatic (MEN1)
- Allelic: Adrenocortical carcinoma, pediatric (TP53)
- Allelic: Adrenocortical tumor, somatic (PRKAR1A)
- Allelic: Angiofibroma, somatic (MEN1)
- Allelic: Basal cell carcinoma 7 (TP53)
- Allelic: Bone marrow failure syndrome 5 (TP53)
- Allelic: Breast cancer, somatic (PIK3CA)
- Allelic: Breast cancer, somatic (TP53)
- Allelic: CLAPO syndrome, somatic (PIK3CA)
- Allelic: CLOVE syndrome, somatic (PIK3CA)
- Allelic: Carcinoid tumor of lung (MEN1)
- Allelic: Cardiofaciocutaneous syndrome (BRAF)
- Allelic: Cardiomyopathy, dilated, 1GG (SDHA)
- Allelic: Central hypoventilation syndrome, congenital (RET)
- Allelic: Choroid plexus papilloma (TP53)
- Allelic: Colorectal cancer (TP53)
- Allelic: Colorectal cancer, hereditary nonpolyposis, type 1 (MSH2)
- Allelic: Colorectal cancer, hereditary nonpolyposis, type 2 (MLH1)
- Allelic: Colorectal cancer, hereditary nonpolyposis, type 4 (PMS2)
- Allelic: Colorectal cancer, hereditary nonpolyposis, type 5 (MSH6)
- Allelic: Colorectal cancer, somatic (BRAF)
- Allelic: Colorectal cancer, somatic (PIK3CA)
- Allelic: Cowden syndrome 5 (PIK3CA)
- Allelic: Deafness, AR 12 (CDH23)
- Allelic: Endometrial cancer, familia (MSH6)
- Allelic: GLOW syndrome, somatic mosaic (DICER1)
- Allelic: Gastric cancer, somatic (PIUK3CA)
- Allelic: Gastrointestinal stromal tumor (SDHB)
- Allelic: Gastrointestinal stromal tumor (SDHC)
- Allelic: Glioma susceptibility 1 (TP53)
- Allelic: Goiter, multinodular 1, with/-out Sertoli-Leydig cell tumors (DICER1)
- Allelic: Hepatocellular carcinoma, somatic (PIK3CA)
- Allelic: Hepatocellular carcinoma, somatic (TP53)
- Allelic: Hirschsprung disease, protection against (RET)
- Allelic: Hirschsprung disease, susceptibility to, 1 (RET)
- Allelic: Keratosis, seborrheic, somatic (PIK3CA)
- Allelic: LEOPARD syndrome 3 (BRAF)
- Allelic: Li-Fraumeni syndrome (TP53)
- Allelic: Lipoma, somatic (MEN1)
- Allelic: Macrodactyly, somatic (PIK3CA)
- Allelic: McCune-Albright syndrome, somatic, mosaic (GNAS)
- Allelic: Medullary thyroid carcinoma (RET)
- Allelic: Megalencephaly-capillary malformation-polymicrogyria syndrome, somatic (PIK3CA)
- Allelic: Melanoma, malignant, somatic (BRAF)
- Allelic: Mismatch repair cancer syndrome 1 (MLH1)
- Allelic: Mismatch repair cancer syndrome 2 (MSH2)
- Allelic: Mismatch repair cancer syndrome 3 (MSH6)
- Allelic: Mismatch repair cancer syndrome 4 (PMS2)
- Allelic: Mitochondrial complex II deficiency, nuclear type 1 (SDHA)
- Allelic: Mitochondrial complex II deficiency, nuclear type 3 (SDHD)
- Allelic: Muir-Torre syndrome (MLH1, MSH2, )
- Allelic: Myxoma, intracardiac (PRLAR1A)
- Allelic: Nasopharyngeal carcinoma, somatic (TP53)
- Allelic: Nevus, epidermal, somatic (PIUK3CA)
- Allelic: Nonsmall cell lung cancer, somatic (BRAF)
- Allelic: Nonsmall cell lung cancer, somatic (PIK3CA)
- Allelic: Noonan syndrome 7 (BRAF)
- Allelic: Osseous heteroplasia, progressive (GNAS)
- Allelic: Osteosarcoma (TP53)
- Allelic: Ovarian cancer, somatic (PIK3CA)
- Allelic: Pancreatic cancer, somatic (TP53)
- Allelic: Paraganglioma + gastric stromal sarcoma (SDHB, SDHC, SDHD)
- Allelic: Paragangliomas 1, with/-out deafness (SDHD)
- Allelic: Paragangliomas 3 (SDHC)
- Allelic: Paragangliomas 4 (SDHB)
- Allelic: Paragangliomas 5 (SDHA)
- Allelic: Parathyroid adenoma, somatic (MEN1)
- Allelic: Pheochromocytoma (RET)
- Allelic: Pheochromocytoma (SDHB)
- Allelic: Pheochromocytoma (SDHD)
- Allelic: Pheochromocytoma, susceptibility to (MAX)
- Allelic: Pigmented nodular adrenocortical disease, primary, 1 (PRKAR1A)
- Allelic: Pleuropulmonary blastoma (DICER1)
- Allelic: Pseudohypoparathyroidism Ia-c (GNAS)
- Allelic: Pseudopseudohypoparathyroidism (GNAS)
- Allelic: Rhabdomyosarcoma, embryonal, 2 (DICER1)
- Allelic: Usher syndrome, type 1D (CDH23)
- Allelic: Usher syndrome, type 1D/F digenic (CDH23)
- Acromegaly due to pituitary adenoma 1, included
- Allelic: Non-syndromic hearing loss (USP48)
- Cardioacrofacial dysplasia 2 (PRKACB)
- Carney complex, type 1; 80% somatotroph cell hyperplasia or small pituitary adenoma (PRKAR1A)
- DICER1 syndrome (DICER1)
- Hereditary paraganglioma-pheochromocytoma syndromes, rarely pituitary disease (MAX, SDHA-D, RET)
- Isolated familial somatotropinoma, included
- Lynch syndrome; rarely pituitary disease (MLH1, MSH2, MSH6, PMS2)
- MEN1-like syndrome; 40% pituitary tumors, mostly somatotropnomas (CDKN1A, CDKN1B, CDKN2B, CDKN2C)
- McCune-Albright syndrome; 30% pituitary disease, GH-adenomas, prolactiemia (GNAS)
- Multiple endocrine neoplasia, type I; 40% pituitary tumors, mostly prolactinomas (MEN1)
- Multiple endocrine neoplasia, type IV (CDKN1B)
- Multiple endocrine neoplasia, types IIA + IIB (RET)
- Nonsyndromic genetic deafness, MONDO:0019497 (USP48)
- Pituitary adenoma 1, multiple types (AIP)
- Pituitary adenoma 2, GH-secreting (GPR101)
- Pituitary adenoma 3, multiple types, somatic (GNAS)
- Pituitary adenoma 4, ACTH-secreting, somatic (USP8)
- Pituitary adenoma 5, multiple types (CDH23)
- Pituitary adenoma predisposition (AIP)
- Pituitary adenoma predisposition (USP8)
- Somatotrophinoma, familial, included
- AD
- AR
- Sus
- XL
- Multiple OMIM-Ps
Bioinformatics and clinical interpretation
Test-Stärken
- DAkkS-akkreditiertes Labor
- EU-Richtlinie für IVD in Umsetzung
- Qualitäts-kontrolliert arbeitendes Personal
- Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
- Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
- eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
- unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
- unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
- unsere umfassenden klinischen Aussagen
Testeinschränkungen
- Gene mit eingeschränkter Abdeckung werden gekennzeichnet
- Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
- es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
- die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
- Gen-Konversionen
- komplexe Inversionen
- Balancierte Translokationen
- Mitochondriale Varianten
- Repeat-Expansionen, sofern nicht anders dokumentiert
- nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
- niedriger Mosaik-Status
- Repeat-Blöcke von Mononukleotiden
- Indels >50bp (Insertionen-Deletionen)
- Deletionen oder Duplikationen einzelner Exons
- Varianten innerhalb von Pseudogenen
- die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde
Laboratory requirement
Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.
Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.
Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.
Die Untersuchung wird auch für Selbstzahler angeboten.